Symphony Financial Ltd. Co. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 45.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,786 shares of the biopharmaceutical company’s stock after acquiring an additional 4,334 shares during the quarter. Symphony Financial Ltd. Co.’s holdings in Pfizer were worth $497,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of New York Mellon Corp lifted its stake in shares of Pfizer by 12.1% in the fourth quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock valued at $2,383,700,000 after buying an additional 6,965,496 shares in the last quarter. Norges Bank acquired a new position in Pfizer during the 4th quarter valued at about $2,219,532,000. Morgan Stanley increased its holdings in Pfizer by 16.4% during the 4th quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock worth $1,973,389,000 after purchasing an additional 7,540,245 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 5.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 42,009,283 shares of the biopharmaceutical company’s stock worth $1,546,362,000 after purchasing an additional 2,012,367 shares during the last quarter. Finally, Sanders Capital LLC lifted its holdings in shares of Pfizer by 10.6% in the fourth quarter. Sanders Capital LLC now owns 31,947,816 shares of the biopharmaceutical company’s stock valued at $1,280,997,000 after purchasing an additional 3,051,838 shares in the last quarter. 67.36% of the stock is owned by institutional investors and hedge funds.
PFE opened at $38.57 on Monday. The company has a market cap of $215.13 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 2.79 and a beta of 0.70. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.76. Pfizer Inc. has a 12 month low of $31.61 and a 12 month high of $43.08. The company has a 50 day moving average of $35.49 and a 200 day moving average of $36.60.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by ($0.04). Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The company had revenue of $11.68 billion during the quarter, compared to analysts’ expectations of $11.32 billion. During the same quarter in the prior year, the firm posted $0.55 EPS. The firm’s quarterly revenue was up 11.8% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on the company. Morgan Stanley lowered their price target on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research report on Friday, January 29th. Royal Bank of Canada started coverage on shares of Pfizer in a research report on Wednesday, April 7th. They set a “sector perform” rating and a $42.00 price target on the stock. JPMorgan Chase & Co. set a $36.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, February 3rd. Mizuho cut their target price on Pfizer from $44.00 to $42.00 and set a “buy” rating on the stock in a research note on Wednesday, February 3rd. Finally, Berenberg Bank reaffirmed a “neutral” rating and set a $38.00 price target on shares of Pfizer in a research report on Tuesday, March 23rd. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $38.47.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
See Also: Trading signals using Bollinger bands
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.